Source: LinkedIn I’m sure you’ve been asked many times whether you’re an introvert or an extrovert. For some people, it’s…...
Latest News
Allergan, Paratek hit late-stage acne goals, prep for sarecycline NDA
Source: FierceBiotech Allergan and partner Paratek Pharmaceuticals have hit their primary endpoints in two key phase 3 acne trials for…...
Cipher Pharmaceuticals Appoints Robert D. Tessarolo as CEO
Source: Cipher Pharmaceuticals Inc. (CPH.TO) ("Cipher" or "the Company") announced today that veteran pharmaceutical industry executive Robert D. Tessarolo has…...
Sun Pharma’s indirect arm Taro to acquire Thallion Pharmaceuticals
Source: Sun Pharmaceutical Industries today said an indirect arm of its group firm Taro will fully acquire Canada’s Thallion Pharmaceuticals…...
Novan Provides Update on SB204 Development Program
Source: Novan MORRISVILLE, N.C., March 06, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that,…...
Allergan continues M&A spree with $2.5B deal to beef up aesthetics unit
Source: Since its massive Pfizer merger fell through last year, Allergan has persisted with “stepping-stone deals” rather than a transformational…...
Encore Dermatology Inc. Announces Launch of TridesilonTM (desonide) Cream, 0.05%
Source: Business Wire Encore Dermatology Inc., a privately held dermatology company that specializes in developing and commercializing novel prescription products…...
Johnson & Johnson refills drug cabinet with $30 billion Actelion deal
Source: Reuters U.S. healthcare giant Johnson & Johnson (JNJ.N) will buy Swiss biotech company Actelion (ATLN.S) in a $30 billion…...
Novan Licenses SB204 to Sato for Acne in Japan
Source: Globe Newswire Novan, Inc. (“the Company” or “Novan”) (NOVN) today announced that the Company has entered into an exclusive…...
Sun Pharma Announces Positive Topline Results of Confirmatory Phase-3 Clinical Trial for Seciera™ for Treatment of Dry Eye
Source: Sun Pharma announced successful Phase 3 confirmatory clinical trial results for Seciera™ (cyclosporine A, 0.09% ophthalmic solution), for the…...